First Time Loading...

C4 Therapeutics Inc
NASDAQ:CCCC

Watchlist Manager
C4 Therapeutics Inc Logo
C4 Therapeutics Inc
NASDAQ:CCCC
Watchlist
Price: 6.24 USD -3.55% Market Closed
Updated: Apr 26, 2024
Section:
 

Wall Street
Price Targets

CCCC Price Targets Summary
C4 Therapeutics Inc

Wall Street analysts forecast CCCC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CCCC is 18.87 USD with a low forecast of 7.07 USD and a high forecast of 63 USD.

CCCC Lowest Forecast
Wall Street Target
7.07 USD
13% Upside
CCCC Average Forecast
Wall Street Target
18.87 USD
202% Upside
CCCC Highest Forecast
Wall Street Target
63 USD
910% Upside
Lowest
Price Target
7.07 USD
13% Upside
Average
Price Target
18.87 USD
202% Upside
Highest
Price Target
63 USD
910% Upside
C4 Therapeutics Inc Competitors:
Price Targets
ABOS
Acumen Pharmaceuticals Inc
309% Upside
4593
Healios KK
108% Upside
S
6990
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
18% Upside
GILD
Gilead Sciences Inc
33% Upside
ABOS
Acumen Pharmaceuticals Inc
309% Upside
4593
Healios KK
108% Upside
S
6990
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
18% Upside
GILD
Gilead Sciences Inc
33% Upside
I
IMRX
Immuneering Corp
829% Upside
BIOA B
BioArctic AB
87% Upside
AURA
Aura Biosciences Inc
185% Upside
688266
Suzhou Zelgen Biopharmaceuticals Co Ltd
16% Upside

Revenue
Forecast

Revenue Estimate
C4 Therapeutics Inc

For the last 4 years the compound annual growth rate for C4 Therapeutics Inc's revenue is -1%. The projected CAGR for the next 3 years is 96%.

-1%
Past Growth
96%
Estimated Growth
Estimates Accuracy
-3%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
C4 Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
C4 Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-35%
Average Miss
What are analyst estimates?

See Also

Summary
CCCC intrinsic value, competitors valuation, and company profile.
DCF Valuation
CCCC stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CCCC stock valuation using valuation multiples.
Wall Street Estimates
CCCC price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CCCC stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CCCC's stock price target?
Price Target
18.87 USD

According to Wall Street analysts, the average 1-year price target for CCCC is 18.87 USD with a low forecast of 7.07 USD and a high forecast of 63 USD.

What is C4 Therapeutics Inc's Revenue forecast?
Projected CAGR
96%

For the last 4 years the compound annual growth rate for C4 Therapeutics Inc's revenue is -1%. The projected CAGR for the next 3 years is 96%.

ALPHA SPREAD
Join more than 131,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.